Maintaining Trust in Newborn Screening: Compliance and Informed Consent in the Netherlands

Newborn screening consists of taking a few drops of blood from a baby's heel in the first week of life and testing it for a list of disorders. In the United States and most countries in Europe, newborn screening programs began in the 1960s and 1970s with screening for phenylketonuria (PKU), a r...

Full description

Saved in:  
Bibliographic Details
Authors: van der Burg, Simone (Author) ; Verweij, Marcel (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Interlibrary Loan:Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany)
Published: 2012
In: The Hastings Center report
Year: 2012, Volume: 42, Issue: 5, Pages: 41-47
Online Access: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000naa a22000002c 4500
001 1937536149
003 DE-627
005 20251002055627.0
007 cr uuu---uuuuu
008 251002s2012 xx |||||o 00| ||eng c
024 7 |a 10.1002/hast.66  |2 doi 
035 |a (DE-627)1937536149 
035 |a (DE-599)KXP1937536149 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a van der Burg, Simone  |e VerfasserIn  |4 aut 
245 1 0 |a Maintaining Trust in Newborn Screening: Compliance and Informed Consent in the Netherlands 
264 1 |c 2012 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Newborn screening consists of taking a few drops of blood from a baby's heel in the first week of life and testing it for a list of disorders. In the United States and most countries in Europe, newborn screening programs began in the 1960s and 1970s with screening for phenylketonuria (PKU), a rare metabolic disease that causes severe and irreversible mental retardation unless treated before problems arise. As knowledge about rare diseases expanded and new screening technologies were introduced—such as the tandem mass spectrometer and high-performance liquid chromatography—the same blood sample could be used to test for a whole list of disorders. In general, screening programs in most countries have tended to expand, but in different countries they have expanded in different ways. Regulation also varies. In some states, screening is mandatory, whereas in others—Wyoming and Maryland—parents are asked for their informed consent. Germany and France have adopted an explicit informed consent procedure, whereas other European countries have a more informal “opt-out” procedure that does not require signing an informed consent form. Whether newborn screening requires informed consent is an ongoing issue in bioethics. In this article, we will focus on the tension between informed consent and the problem of compliance in newborn screening. Asking for informed consent—allowing parents to opt out—is often thought to pose a threat to compliance. Building on the work of Onora O'Neill on informed consent and trust, however, as well as on work she coauthored with Neil Manson, we will argue that informed consent procedures may actually help maintain trust in newborn screening and may therefore support compliance. 
601 |a Compliance 
700 1 |a Verweij, Marcel  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a Hastings Center  |t The Hastings Center report  |d Malden, Mass. : Wiley, 1971  |g 42(2012), 5, Seite 41-47  |h Online-Ressource  |w (DE-627)341346551  |w (DE-600)2067369-3  |w (DE-576)258761822  |x 1552-146X  |7 nnas 
773 1 8 |g volume:42  |g year:2012  |g number:5  |g pages:41-47 
856 4 0 |u https://doi.org/10.1002/hast.66  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.66  |x Verlag  |z lizenzpflichtig  |3 Volltext 
912 |a NOMM 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4779662338 
LOK |0 003 DE-627 
LOK |0 004 1937536149 
LOK |0 005 20251002055627 
LOK |0 008 251002||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2025-09-26#A99074B26E0FB923F7E05D7C1220F340FE6C09A8 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixrk  |a ixzs  |a zota  |a tiep 
ORI |a TA-MARC-ixtheoa001.raw